Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Interleukin-6.

Articles de revues sur le sujet « Interleukin-6 »

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Interleukin-6 ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

&NA;. "Interleukin-3/interleukin-6." Reactions Weekly &NA;, no. 550 (1995): 11. http://dx.doi.org/10.2165/00128415-199505500-00035.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

&NA;. "Interleukin-6." Reactions Weekly &NA;, no. 570 (1995): 9. http://dx.doi.org/10.2165/00128415-199505700-00023.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Lotz, Martin. "Interleukin-6." Cancer Investigation 11, no. 6 (1993): 732–42. http://dx.doi.org/10.3109/07357909309046948.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

&NA;. "Interleukin 6." Inpharma Weekly &NA;, no. 877 (1993): 2. http://dx.doi.org/10.2165/00128413-199308770-00001.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

&NA;. "Interleukin 6." Reactions Weekly &NA;, no. 505 (1994): 8. http://dx.doi.org/10.2165/00128415-199405050-00037.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

&NA;. "Interleukin 6." Reactions Weekly &NA;, no. 531 (1994): 8. http://dx.doi.org/10.2165/00128415-199405310-00027.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Song, Mingchen, and John A. Kellum. "Interleukin-6." Critical Care Medicine 33, Suppl (2005): S463—S465. http://dx.doi.org/10.1097/01.ccm.0000186784.62662.a1.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

CASTELL, JOSé V., TILO ANDUS, DIETER KUNZ, and PETER C. HEINRICH. "Interleukin-6." Annals of the New York Academy of Sciences 557, no. 1 (2008): 87–101. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24001.x.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

LEE, FRANK, CHOY-PIK CHIU, JANUSZ WIDEMAN, et al. "Interleukin-6." Annals of the New York Academy of Sciences 557, no. 1 (2008): 215–29. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24015.x.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

CLARK, STEVEN C. "Interleukin-6." Annals of the New York Academy of Sciences 557, no. 1 (2008): 438–43. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24036.x.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
11

Olencki, Thomas, James Finke, and Ronald M. Bukowski. "Interleukin-6." Clinical Immunotherapeutics 2, no. 4 (1994): 278–94. http://dx.doi.org/10.1007/bf03258528.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
12

Sin, Don D., and S. F. Paul Man. "Interleukin-6." Chest 133, no. 1 (2008): 4–6. http://dx.doi.org/10.1378/chest.07-2085.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
13

Delk, Nikki A., and Mary C. Farach-Carson. "Interleukin-6." Autophagy 8, no. 4 (2012): 650–63. http://dx.doi.org/10.4161/auto.19226.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
14

Matsuda, Tadashi, and Toshio Hirano. "Interleukin 6 (IL-6)." Biotherapy 2, no. 4 (1990): 363–73. http://dx.doi.org/10.1007/bf02170085.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
15

Annisa, Yuanita Anggreini1 GontarAlamsyah Siregar*2 &. Leonardo Basa Dairi3. "ASSOCIATION BETWEEN INTERLEUKIN 6 SERUM LEVEL AND NON-ALCOHOLIC FATTY LIVER DISEASE." INTERNATIONAL JOURNAL OF RESEARCH SCIENCE & MANAGEMENT 6, no. 7 (2019): 11–16. https://doi.org/10.5281/zenodo.3342743.

Texte intégral
Résumé :
<strong>Background. </strong>Non-Alcoholic Fatty Liver Disease (NAFLD) emerged as a major health problem throughout the world and is increasing as the prevalence of obesity and diabetes continues to increase and is recognized as a major cause of liver disease-related morbidity and mortality. Adipokine is critically involved in healthy liver physiology and in the pathophysiology of acute and chronic liver disease as an intermediary for liver inflammation, liver cell death, cholestasis, and fibrosis. Interleukin-6 (IL-6) is one of adipokines widely studied recently. IL-6 showed improvement and p
Styles APA, Harvard, Vancouver, ISO, etc.
16

Rivera-Chavez, Fernando A., Dixie L. Peters-Hybki, Robert C. Barber, and Grant E. O'Keefe. "Interleukin-6 Promoter Haplotypes and Interleukin-6 Cytokine Responses." Shock 20, no. 3 (2003): 218–23. http://dx.doi.org/10.1097/00024382-200309000-00004.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
17

Ridker, Paul M. "Targeting Interleukin-1 and Interleukin-6." Journal of the American College of Cardiology 76, no. 15 (2020): 1774–76. http://dx.doi.org/10.1016/j.jacc.2020.08.052.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
18

NORTHEMANN, WOLFGANG, TODD A. BFUCIAK, MASAHIRA HATTORI, and GEORG H. FEY. "Rat Interleukin-6." Annals of the New York Academy of Sciences 557, no. 1 (2008): 536–39. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24057.x.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
19

Schneider, Kirsten, Reinhard Klaas, Bernd Kaspers, and Peter Staeheli. "Chicken interleukin-6." European Journal of Biochemistry 268, no. 15 (2001): 4200–4206. http://dx.doi.org/10.1046/j.1432-1327.2001.02334.x.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
20

Tamura, T., N. Udagawa, N. Takahashi, et al. "Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6." Proceedings of the National Academy of Sciences 90, no. 24 (1993): 11924–28. http://dx.doi.org/10.1073/pnas.90.24.11924.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
21

Ogawa, Michio, Kiyoshi Sakamoto, Seiji Mita, Takatoshi Ishiko, and Saburo Hisano. "INTERLEUKIN-6 AND SOLUBLE INTERLEUKIN-6 RECEPTOR IN SURGICAL TRAUMA." Shock 4, Supplement (1995): 11. http://dx.doi.org/10.1097/00024382-199512001-00045.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
22

De Filippo, G., D. Rendina, F. Moccia, V. Rocco, and A. Campanozzi. "Interleukin-6, soluble interleukin-6 receptor/interleukin-6 complex and insulin resistance in obese children and adolescents." Journal of Endocrinological Investigation 38, no. 3 (2014): 339–43. http://dx.doi.org/10.1007/s40618-014-0176-4.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
23

Oka, Masaaki, Hiroshi Kusanagi, Toshihiro Saeki, et al. "Interleukin-6 Production and Interleukin-6 Receptor Expression in Human Esophageal Cancer Cell Lines." Japanese Journal of Gastroenterological Surgery 26, no. 11 (1993): 2707. http://dx.doi.org/10.5833/jjgs.26.2707.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
24

Prens, Errol P., Klazina Benne, Jozef van Damme, et al. "Interleukin-1 and Interleukin-6 in Psoriasis." Journal of Investigative Dermatology 95, no. 6 (1990): S121—S124. http://dx.doi.org/10.1111/1523-1747.ep12874991.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
25

Bota, Rafaqat, and Mushtaq Ahmed. "The pathophysiological profile of interleukin-6 and anti-interleukin-6 antibody." El Mednifico Journal 1, no. 2 (2013): 51. http://dx.doi.org/10.18035/emj.v1i2.26.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
26

Ridker, Paul M., and Manas Rane. "Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease." Circulation Research 128, no. 11 (2021): 1728–46. http://dx.doi.org/10.1161/circresaha.121.319077.

Texte intégral
Résumé :
IL (interleukin)-6 is a pivotal cytokine of innate immunity, which enacts a broad set of physiological functions traditionally associated with host defense, immune cell regulation, proliferation, and differentiation. Following recognition of innate immune pathways leading from the NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome to IL-1 to IL-6 and on to the hepatically derived clinical biomarker CRP (C-reactive protein), an expanding literature has led to understanding of the proatherogenic role for IL-6 in cardiovascular disease and thus the potential for IL-6 inhibitio
Styles APA, Harvard, Vancouver, ISO, etc.
27

Jucker, M., H. Abts, W. Li, et al. "Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease." Blood 77, no. 11 (1991): 2413–18. http://dx.doi.org/10.1182/blood.v77.11.2413.2413.

Texte intégral
Résumé :
Abstract Interleukin-6 (IL-6) is a multipotent lymphokine that can mediate differentiation of B cells into Ig-secreting cells, stimulate the growth of plasmacytomas, hybridomas, and T cells, and induce acute- phase proteins in liver cells. It has been suggested that IL-6 is involved in the pathogenesis of several diseases by autocrine or paracrine pathways. To examine whether IL-6 is possibly involved in the pathophysiology of Hodgkin's disease (HD), we analyzed the expression of IL-6 and IL-6 receptor mRNA and protein in cell lines and primary specimens from patients with HD. IL-6-specific tr
Styles APA, Harvard, Vancouver, ISO, etc.
28

Jucker, M., H. Abts, W. Li, et al. "Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease." Blood 77, no. 11 (1991): 2413–18. http://dx.doi.org/10.1182/blood.v77.11.2413.bloodjournal77112413.

Texte intégral
Résumé :
Interleukin-6 (IL-6) is a multipotent lymphokine that can mediate differentiation of B cells into Ig-secreting cells, stimulate the growth of plasmacytomas, hybridomas, and T cells, and induce acute- phase proteins in liver cells. It has been suggested that IL-6 is involved in the pathogenesis of several diseases by autocrine or paracrine pathways. To examine whether IL-6 is possibly involved in the pathophysiology of Hodgkin's disease (HD), we analyzed the expression of IL-6 and IL-6 receptor mRNA and protein in cell lines and primary specimens from patients with HD. IL-6-specific transcripts
Styles APA, Harvard, Vancouver, ISO, etc.
29

Plenz, Gabriele, Heike Eschert, Michael Erren, et al. "The interleukin-6/interleukin-6-receptorsystem is activated in donor hearts." Journal of the American College of Cardiology 39, no. 9 (2002): 1508–12. http://dx.doi.org/10.1016/s0735-1097(02)01791-6.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
30

Nancey, Stéphane, Nadim Hamzaoui, Driffa Moussata, Ivan Graber, Jacques Bienvenu, and Bernard Flourie. "Serum Interleukin-6, Soluble Interleukin-6 Receptor and Crohn’s Disease Activity." Digestive Diseases and Sciences 53, no. 1 (2007): 242–47. http://dx.doi.org/10.1007/s10620-007-9849-6.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
31

Angelis, Pela, Simon Scharf, Alastair Mander, Frank Vajda, and Nicholas Christophidis. "Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease." Neuroscience Letters 244, no. 2 (1998): 106–8. http://dx.doi.org/10.1016/s0304-3940(98)00136-0.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
32

Rezai, Ali R., Ahmad Rezai, Otoniel Mart�nez-Maza, Meta Vander-Meyden, and Martin H. Weiss. "Interleukin-6 and interleukin-6 receptor gene expression in pituitary tumors." Journal of Neuro-Oncology 19, no. 2 (1994): 131–35. http://dx.doi.org/10.1007/bf01306454.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
33

MONTERO-JULIAN, F. A., E. GAUTHEROT, J. WIJDENES, B. KLEIN, and H. BRAILLY. "Pharmacokinetics of Interleukin-6 During Therapy with Anti-Interleukin-6 Monoclonal Antibodies: Enhanced Clearance of Interleukin-6 by a Combination of Three Anti-Interleukin-6 Antibodies." Journal of Interferon Research 14, no. 5 (1994): 301–2. http://dx.doi.org/10.1089/jir.1994.14.301.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
34

KENIS, G., C. TEUNISSEN, R. DEJONGH, E. BOSMANS, H. STEINBUSCH, and M. MAES. "STABILITY OF INTERLEUKIN 6, SOLUBLE INTERLEUKIN 6 RECEPTOR, INTERLEUKIN 10 AND CC16 IN HUMAN SERUM." Cytokine 19, no. 5 (2002): 228–35. http://dx.doi.org/10.1016/s1043-4666(02)91961-7.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
35

Kenis, Gunter, Charlotte Teunissen, Raf De Jongh, Eugène Bosmans, Harry Steinbusch, and Michael Maes. "STABILITY OF INTERLEUKIN 6, SOLUBLE INTERLEUKIN 6 RECEPTOR, INTERLEUKIN 10 AND CC16 IN HUMAN SERUM." Cytokine 19, no. 5 (2002): 228–35. http://dx.doi.org/10.1006/cyto.2002.1961.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
36

HIRANO, TOSHIO. "Interleukin 6 (IL-6) and disease." Japanese Journal of Clinical Immunology 13, no. 5 (1990): 444–45. http://dx.doi.org/10.2177/jsci.13.444.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
37

Van Wagoner, N. J., and E. N. Benveniste. "Interleukin-6 regulation in human astrocytes: Synergy between TNF-alpha, interleukin-6, and the soluble-interleukin-6 receptor-alpha." Journal of Neuroimmunology 90, no. 1 (1998): 53. http://dx.doi.org/10.1016/s0165-5728(98)91497-7.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
38

Abasova, Dunya, Sevda Kazimova, Nazrin Macidova, Telli Shirinova, and Shalala Babayeva. "STUDY OF STOKIN STATUS IN PATIENTS WITH TOXOPLASMOSIS." Annali d'Italia 50 (December 26, 2023): 17–19. https://doi.org/10.5281/zenodo.10432472.

Texte intégral
Résumé :
The problem of opportunistic infections is becoming an urgent problem of modern times is becoming, which&nbsp;is a constant increase in the number of people infected with HIV, it is related to the increase in aggressive treatment&nbsp;methods of oncopathologies. This infections Pathogens that can normally cause disease in healthy individuals&nbsp;caused by Up to 20 typical causative agents of opportunistic infections are known, and in modern infectious diseases this list is constantly growing. without symptoms: 60% - cytomegalovirus, 90% - first and second type herpavirus, 30% are toxoplasma c
Styles APA, Harvard, Vancouver, ISO, etc.
39

Sajjad, Kathem Ashour, Abd Jabbar Al-Ammar Haider, and Hamza Sharif Yasmine. "Interleukin-6 Biomarker as Possible Predicator of Preeclampsia." Biomedicine and Chemical Sciences, no. 4 (September 30, 2022): 306–11. https://doi.org/10.48112/bcs.v1i4.303.

Texte intégral
Résumé :
Preeclampsia (PE) is a serious illness that can harm both mothers and unborn children and may even be fatal. It contributes significantly to maternal fatalities in underdeveloped countries. PE, which affects 2%&ndash;3% of women who are pregnant after 20 weeks of pregnancy, is marked by proteinuria and hypertension. PE is a significant condition that plays a significant role in maternal fatalities in underdeveloped countries and is a significant cause of death for both mothers and newborns. Each year, around 60,000 maternal fatalities occur in the world. Serum interleukin-6 (IL-6) was measured
Styles APA, Harvard, Vancouver, ISO, etc.
40

Hoejberg, Lise, Lars Bastholt, and Henrik Schmidt. "Interleukin-6 and melanoma." Melanoma Research 22, no. 5 (2012): 327–33. http://dx.doi.org/10.1097/cmr.0b013e3283543d72.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
41

Rose-John, Stefan. "Interleukin-6 Family Cytokines." Cold Spring Harbor Perspectives in Biology 10, no. 2 (2017): a028415. http://dx.doi.org/10.1101/cshperspect.a028415.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
42

Tanaka, Toshio, Masashi Narazaki, and Tadamitsu Kishimoto. "Interleukin (IL-6) Immunotherapy." Cold Spring Harbor Perspectives in Biology 10, no. 8 (2017): a028456. http://dx.doi.org/10.1101/cshperspect.a028456.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
43

Suzuki, Kenshi, Akiko Miyashita, Yasuyuki Inoue, et al. "Interleukin-6-Producing Pheochromocytoma." Acta Haematologica 85, no. 4 (1991): 217–19. http://dx.doi.org/10.1159/000204897.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
44

Kerr, Ron, David Stirling, and Christopher A. Ludlam. "Interleukin 6 and Haemostasis." British Journal of Haematology 115, no. 1 (2001): 3–12. http://dx.doi.org/10.1046/j.1365-2141.2001.03061.x.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
45

Nagila, Amar, Khem Raj Paudel, and Bijay Subedi. "Interleukin-6 in Hypothyroidism." Journal of Manmohan Memorial Institute of Health Sciences 9, no. 2 (2024): 27–29. http://dx.doi.org/10.3126/jmmihs.v9i2.71838.

Texte intégral
Résumé :
Background: Hypothyroidism means that the thyroid gland can’t produce enough thyroid hormones. Interleukin 6 (IL-6) a cytokine of innate immunity is a soluble mediator with a pleotropic effect on inflammation. Interleukin 6 test is helpful to study the hypothyroid status and to assess the adverse effects of hypothyroidism, was not studied in a tertiary care center in Pokhara, Nepal. The aim of this study is to determine the levels of interleukin 6 and to correlate with hypothyroidism. Methodology: This was a hospital based cross-sectional study on 100 hypothyroid patients where samples were co
Styles APA, Harvard, Vancouver, ISO, etc.
46

Sehgal, Pravinkumar B. "Interleukin-6: Molecular Pathophysiology." Journal of Investigative Dermatology 94, no. 6 (1990): s2—s6. http://dx.doi.org/10.1111/1523-1747.ep12874963.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
47

Van Snick, Jacques. "Interleukin-6: An Overview." Annual Review of Immunology 8, no. 1 (1990): 253–78. http://dx.doi.org/10.1146/annurev.iy.08.040190.001345.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
48

Pedersen, Bente Klarlund, Adam Steensberg, and Peter Schjerling. "Exercise and interleukin-6." Current Opinion in Hematology 8, no. 3 (2001): 137–41. http://dx.doi.org/10.1097/00062752-200105000-00002.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
49

Patarca, Roberto, and Mary Ann Fletcher. "Interleukin-6 and Disease." Journal of Chronic Fatigue Syndrome 4, no. 1 (1998): 53–69. http://dx.doi.org/10.1300/j092v04n01_07.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
50

SEHGAL, PRAVIN B., LING WANG, RAVI RAYANADE, HENG PAN, and LOLA MARGULIES. "Interleukin-6-Type Cytokinesa." Annals of the New York Academy of Sciences 762, no. 1 (2006): 1–14. http://dx.doi.org/10.1111/j.1749-6632.1995.tb32309.x.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!